Reid Hoffman Departs Microsoft’s Board to Focus on AI Startup Manus
Reid Hoffman, co-founder of LinkedIn and a prominent figure in the tech industry, has announced his departure from Microsoft’s board of directors to dedicate his efforts to his latest venture, Manus, an artificial intelligence (AI) startup specializing in drug discovery. This decision marks a significant shift in Hoffman’s career, emphasizing his commitment to advancing AI applications in healthcare.
A Decade of Influence at Microsoft
Hoffman’s association with Microsoft began in 2016 following the tech giant’s acquisition of LinkedIn for $26.2 billion. His tenure on the board has been marked by strategic decisions that have significantly influenced Microsoft’s direction, particularly in the realm of AI. In 2019, Hoffman was instrumental in Microsoft’s initial $1 billion investment in OpenAI, a move that underscored the company’s commitment to AI research and development. Hoffman, an original investor in OpenAI, served on its board until 2023, stepping down due to potential conflicts of interest.
Further demonstrating his influence, Hoffman was present during Microsoft’s $650 million acqui-hire deal with Inflection AI, an AI startup he co-founded. This strategic move led to the integration of Inflection’s co-founder, Mustafa Suleyman, into Microsoft’s team, highlighting the company’s aggressive pursuit of AI talent and technology.
Embracing ‘Founder Mode’ with Manus
In a recent episode of his Possible podcast, Hoffman discussed his decision to transition into founder mode with Manus. The startup, which focuses on leveraging AI for drug discovery, particularly in combating various forms of cancer, has garnered significant attention and investment. Last year, Manus successfully raised over $50 million through multiple seed funding rounds, with contributions from Hoffman and venture capital firm General Catalyst.
While Hoffman serves as a co-founder and chairman of Manus, the role of CEO is held by Dr. Siddhartha Mukherjee, a renowned physician, biologist, and Pulitzer Prize-winning author of The Emperor of All Maladies: A Biography of Cancer. This leadership structure combines Hoffman’s entrepreneurial expertise with Dr. Mukherjee’s deep medical knowledge, positioning Manus at the forefront of AI-driven medical innovation.
Advancing ‘Move 37’ AI in Drug Discovery
Hoffman has expressed enthusiasm about Manus’s progress, particularly in developing what he refers to as Move 37 AI. This term, inspired by a pivotal moment in the game of Go where AI demonstrated creativity beyond human capability, signifies AI’s potential to surpass human creativity in fields like chemistry. Manus aims to harness this advanced AI to revolutionize drug discovery processes, offering new hope in the fight against cancer.
A Legacy of Innovation and Strategic Vision
Hoffman’s departure from Microsoft’s board reflects his enduring passion for innovation and his belief in AI’s transformative potential. His strategic decisions have not only shaped Microsoft’s AI initiatives but have also influenced the broader tech landscape. By focusing on Manus, Hoffman continues to push the boundaries of technology, aiming to make significant contributions to healthcare through AI.
